{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/04/19/3276675/0/en/Monopar-Presents-Phase-3-Data-Showing-Greater-Neurologic-Benefit-with-ALXN1840-vs-SoC-in-Wilson-Disease-Patients-with-Neurologic-Symptoms-at-AAN-2026.html", "message": "News view counter 670657 successfully enlarged"}